T1	PROC 1 22	Estudio multicéntrico
#1	AnnotatorNotes T1	C1096776; Multicenter Study; Research Activity
T2	PROC 49 60	tratamiento
#2	AnnotatorNotes T2	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T3	CHEM 282 298	darbepoetin alfa
#3	AnnotatorNotes T3	C0937950; darbepoetin alfa; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T4	DISO 67 73	anemia
#4	AnnotatorNotes T4	C0002871; Anemia; Disease or Syndrome
T5	PROC 133 192	ensayo clínico prospectivo, multicéntrico, de un solo brazo
T6	PROC 480 488	tratados
#5	AnnotatorNotes T6	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T7	DISO 87 114	insuficiencia renal crónica
#6	AnnotatorNotes T7	C0403447; Chronic Kidney Insufficiency; Disease or Syndrome | C1561643; Chronic Kidney Diseases; Disease or Syndrome
T8	CHEM 244 255	hemoglobina
#7	AnnotatorNotes T8	C0019046; Hemoglobin; Amino Acid, Peptide, or Protein · Biologically Active Substance
T9	CHEM 257 259	Hb
#8	AnnotatorNotes T9	C0019046; Hemoglobin; Amino Acid, Peptide, or Protein · Biologically Active Substance
T10	PROC 322 333	tratamiento
#9	AnnotatorNotes T10	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T11	DISO 352 379	insuficiencia renal crónica
#10	AnnotatorNotes T11	C0403447; Chronic Kidney Insufficiency; Disease or Syndrome | C1561643; Chronic Kidney Diseases; Disease or Syndrome
T12	DISO 381 384	IRC
#11	AnnotatorNotes T12	C0403447; Chronic Kidney Insufficiency; Disease or Syndrome | C1561643; Chronic Kidney Diseases; Disease or Syndrome
T13	PROC 403 415	hemodiálisis
#12	AnnotatorNotes T13	C0019004; Hemodialysis; Therapeutic or Preventive Procedure
T14	PROC 420 439	diálisis peritoneal
#13	AnnotatorNotes T14	C0031139; Peritoneal Dialysis; Therapeutic or Preventive Procedure
T15	CHEM 458 460	Hb
#14	AnnotatorNotes T15	C0019046; Hemoglobin; Amino Acid, Peptide, or Protein · Biologically Active Substance
T16	DISO 2090 2093	IRC
#15	AnnotatorNotes T16	C0403447; Chronic Kidney Insufficiency; Disease or Syndrome | C1561643; Chronic Kidney Diseases; Disease or Syndrome
T17	CHEM 636 643	r-HuEPO
#16	AnnotatorNotes T17	C0376541; Recombinant Erythropoietin; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T18	CHEM 622 624	Hb
#17	AnnotatorNotes T18	C0019046; Hemoglobin; Amino Acid, Peptide, or Protein · Biologically Active Substance
T19	PROC 736 757	análisis de seguridad
#18	AnnotatorNotes T19	C1705187; Safety Study; Research Activity
T20	PROC 828 838	titulación
#19	AnnotatorNotes T20	C4761127; Drug titration; Therapeutic or Preventive Procedure
T21	PROC 848 858	evaluación
#20	AnnotatorNotes T21	C1261322; Evaluation procedure; Health Care Activity
T22	CHEM 986 995	peptídica
#21	AnnotatorNotes T22	C0030956; Peptides; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T23	PROC 1126 1137	tratamiento
#22	AnnotatorNotes T23	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T24	PROC 1487 1497	evaluación
#23	AnnotatorNotes T24	C1261322; Evaluation procedure; Health Care Activity
T25	PROC 1311 1322	tratamiento
#24	AnnotatorNotes T25	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T26	CHEM 1435 1437	Hb
#25	AnnotatorNotes T26	C0019046; Hemoglobin; Amino Acid, Peptide, or Protein · Biologically Active Substance
T27	PROC 2409 2423	administración
#26	AnnotatorNotes T27	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T28	CHEM 1752 1768	darbepoetin alfa
#27	AnnotatorNotes T28	C0937950; darbepoetin alfa; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T29	CHEM 1898 1914	darbepoetin alfa
#28	AnnotatorNotes T29	C0937950; darbepoetin alfa; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T30	CHEM 2021 2028	r-HuEPO
#29	AnnotatorNotes T30	C0376541; Recombinant Erythropoietin; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T31	CHEM 1699 1701	Hb
#30	AnnotatorNotes T31	C0019046; Hemoglobin; Amino Acid, Peptide, or Protein · Biologically Active Substance
T32	CHEM 2033 2049	darbepoetin alfa
#31	AnnotatorNotes T32	C0937950; darbepoetin alfa; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T33	CHEM 2243 2250	r-HuEPO
#32	AnnotatorNotes T33	C0376541; Recombinant Erythropoietin; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T34	CHEM 2252 2268	Darbepoetin alfa
#33	AnnotatorNotes T34	C0937950; darbepoetin alfa; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T35	PROC 2321 2334	niveles de Hb
#34	AnnotatorNotes T35	C0518015; Hemoglobin measurement; Laboratory Procedure
T36	PROC 1882 1893	tratamiento
#35	AnnotatorNotes T36	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T37	DISO 1950 1986	acontecimientos adversos inesperados
#36	AnnotatorNotes T37	C1519789; Unexpected Adverse Event; Finding
T38	PROC 2056 2063	terapia
#37	AnnotatorNotes T38	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T39	PROC 2455 2474	tratados por vía iv
#38	AnnotatorNotes T39	C0455142; Intravenous therapy; Therapeutic or Preventive Procedure
T40	DISO 2070 2076	anemia
#39	AnnotatorNotes T40	C0002871; Anemia; Disease or Syndrome
T41	PROC 2220 2231	tratamiento
#40	AnnotatorNotes T41	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T42	CHEM 2332 2334	Hb
#41	AnnotatorNotes T42	C0019046; Hemoglobin; Amino Acid, Peptide, or Protein · Biologically Active Substance
T43	ANAT 101 106	renal
#42	AnnotatorNotes T43	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T44	PROC 118 126	diálisis
#43	AnnotatorNotes T44	C0011946; Dialysis procedure; Therapeutic or Preventive Procedure | C4551529; Renal Dialysis; Therapeutic or Preventive Procedure
T45	PROC 225 255	concentraciones de hemoglobina
#44	AnnotatorNotes T45	C0518015; Hemoglobin measurement; Laboratory Procedure
T46	CHEM 561 568	r-HuEPO
#45	AnnotatorNotes T46	C0376541; Recombinant Erythropoietin; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T47	ANAT 366 371	renal
#46	AnnotatorNotes T47	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T48	PROC 389 397	diálisis
#47	AnnotatorNotes T48	C0011946; Dialysis procedure; Therapeutic or Preventive Procedure | C4551529; Renal Dialysis; Therapeutic or Preventive Procedure
T49	Route 429 439	peritoneal
#48	AnnotatorNotes T49	C1706534; Peritoneal dialysis route; Functional Concept
T50	PROC 441 460	concentración de Hb
#49	AnnotatorNotes T50	C0518015; Hemoglobin measurement; Laboratory Procedure
T51	CHEM 525 559	eritropoyetina recombinante humana
#50	AnnotatorNotes T51	C0376541; Recombinant Erythropoietin; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T52	PROC 603 624	concentraciones de Hb
#51	AnnotatorNotes T52	C0518015; Hemoglobin measurement; Laboratory Procedure
T53	CHEM 1081 1097	darbepoetin alfa
#52	AnnotatorNotes T53	C0937950; darbepoetin alfa; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T54	PROC 1418 1437	concentración de Hb
#53	AnnotatorNotes T54	C0518015; Hemoglobin measurement; Laboratory Procedure
T55	PROC 2110 2118	diálisis
#54	AnnotatorNotes T55	C0011946; Dialysis procedure; Therapeutic or Preventive Procedure | C4551529; Renal Dialysis; Therapeutic or Preventive Procedure
T56	PROC 2174 2188	administración
#55	AnnotatorNotes T56	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T57	CHEM 26 42	darbepoetin alfa
#56	AnnotatorNotes T57	C0937950; darbepoetin alfa; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T58	CHEM 691 707	darbepoetin alfa
#57	AnnotatorNotes T58	C0937950; darbepoetin alfa; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T59	CHEM 785 801	darbepoetin alfa
#58	AnnotatorNotes T59	C0937950; darbepoetin alfa; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T60	CHEM 881 897	darbepoetin alfa
#59	AnnotatorNotes T60	C0937950; darbepoetin alfa; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T61	CHEM 942 949	r-HuEPO
#60	AnnotatorNotes T61	C0376541; Recombinant Erythropoietin; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T62	CHEM 1149 1156	r-HuEPO
#61	AnnotatorNotes T62	C0376541; Recombinant Erythropoietin; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T63	CHEM 1212 1219	r-HuEPO
#62	AnnotatorNotes T63	C0376541; Recombinant Erythropoietin; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T64	Duration 107 114	crónica
#63	AnnotatorNotes T64	C0205191; chronic; Temporal Concept
T66	LIVB 338 347	pacientes
#64	AnnotatorNotes T66	C0030705; Patients; Patient or Disabled Group
T67	Duration 372 379	crónica
#65	AnnotatorNotes T67	C0205191; chronic; Temporal Concept
T70	LIVB 589 598	pacientes
#66	AnnotatorNotes T70	C0030705; Patients; Patient or Disabled Group
T71	Dose 669 687	al menos una dosis
T72	LIVB 764 773	pacientes
#67	AnnotatorNotes T72	C0030705; Patients; Patient or Disabled Group
T73	Duration 810 820	24 semanas
T74	DEVI 1035 1053	jeringa precargada
#68	AnnotatorNotes T74	C1609474; Prefilled Syringe; Medical Device
T76	Frequency 1098 1108	1 × semana
T77	LIVB 1113 1122	pacientes
#69	AnnotatorNotes T77	C0030705; Patients; Patient or Disabled Group
T78	Frequency 1157 1169	2-3 × semana
T79	Frequency 1173 1189	cada dos semanas
T80	LIVB 1198 1207	pacientes
#70	AnnotatorNotes T80	C0030705; Patients; Patient or Disabled Group
T81	Frequency 1220 1230	1 × semana
T82	LIVB 1249 1258	pacientes
#71	AnnotatorNotes T82	C0030705; Patients; Patient or Disabled Group
T83	Duration 1271 1285	las 24 semanas
T85	Route 1610 1616	vía iv
#72	AnnotatorNotes T85	C1522726; Intravenous Route of Drug Administration; Functional Concept
T86	Route 1668 1674	vía sc
#73	AnnotatorNotes T86	C1522438; Subcutaneous Route of Drug Administration; Functional Concept
T87	Route 1832 1838	vía iv
#74	AnnotatorNotes T87	C1522726; Intravenous Route of Drug Administration; Functional Concept
T88	Route 1869 1875	vía sc
#75	AnnotatorNotes T88	C1522438; Subcutaneous Route of Drug Administration; Functional Concept
T89	Neg_cue 1934 1936	no
T91	LIVB 2097 2106	pacientes
#76	AnnotatorNotes T91	C0030705; Patients; Patient or Disabled Group
T92	Frequency 2269 2285	1 vez por semana
T93	Frequency 2288 2308	1 vez cada 2 semanas
T94	LIVB 2445 2454	pacientes
#77	AnnotatorNotes T94	C0030705; Patients; Patient or Disabled Group
T95	Route 2468 2474	vía iv
#78	AnnotatorNotes T95	C1522726; Intravenous Route of Drug Administration; Functional Concept
T65	PROC 1721 1748	reducción media de la dosis
#79	AnnotatorNotes T65	C2348004; Agent Dose Decreased; Therapeutic or Preventive Procedure
T68	PROC 2369 2390	reducción de la dosis
#80	AnnotatorNotes T68	C2348004; Agent Dose Decreased; Therapeutic or Preventive Procedure
T69	PROC 1460 1466	visita
#81	AnnotatorNotes T69	C1512346; Patient Visit; Health Care Activity
T75	Quantifier_or_Qualifier 1467 1472	basal
#82	AnnotatorNotes T75	C1442488; Baseline; Quantitative Concept
A1	Assertion T37 Negated
R1	Causes Arg1:T7 Arg2:T4	
R2	Location_of Arg1:T43 Arg2:T7	
R3	Has_Duration_or_Interval Arg1:T7 Arg2:T64	
R5	Used_for Arg1:T57 Arg2:T2	
R7	Used_for Arg1:T3 Arg2:T10	
R8	Experiences Arg1:T66 Arg2:T10	
R9	Experiences Arg1:T66 Arg2:T11	
R10	Experiences Arg1:T66 Arg2:T45	
R11	Location_of Arg1:T47 Arg2:T11	
R12	Has_Duration_or_Interval Arg1:T11 Arg2:T67	
R13	Has_Duration_or_Interval Arg1:T12 Arg2:T67	
R14	Location_of Arg1:T47 Arg2:T12	
R17	Experiences Arg1:T66 Arg2:T12	
R18	Experiences Arg1:T66 Arg2:T48	
R19	Experiences Arg1:T66 Arg2:T13	
R20	Experiences Arg1:T66 Arg2:T14	
R21	Has_Route_or_Mode Arg1:T14 Arg2:T49	
R22	Experiences Arg1:T66 Arg2:T50	
T84	Quantifier_or_Qualifier 461 466	basal
#83	AnnotatorNotes T84	C1442488; Baseline; Quantitative Concept
R23	Has_Quantifier_or_Qualifier Arg1:T50 Arg2:T84	
R24	Used_for Arg1:T51 Arg2:T6	
R25	Used_for Arg1:T46 Arg2:T6	
R26	Experiences Arg1:T66 Arg2:T6	
R27	Experiences Arg1:T70 Arg2:T52	
R28	Experiences Arg1:T70 Arg2:T17	
T90	Dose 627 632;644 652	dosis estables
R29	Has_Dose_or_Strength Arg1:T17 Arg2:T90	
R31	Has_Dose_or_Strength Arg1:T58 Arg2:T71	
R30	Experiences Arg1:T70 Arg2:T58	
T96	Quantifier_or_Qualifier 644 652	estables
R32	Has_Quantifier_or_Qualifier Arg1:T52 Arg2:T96	
R33	Before Arg1:T51 Arg2:T3	
R34	Before Arg1:T46 Arg2:T3	
T97	CONC 498 520	inicio de este estudio
#84	AnnotatorNotes T97	C4684789; Study Start; Temporal Concept
R35	Before Arg1:T6 Arg2:T97	
R36	Before Arg1:T17 Arg2:T58	
R38	Experiences Arg1:T72 Arg2:T59	
R39	Has_Duration_or_Interval Arg1:T59 Arg2:T73	
R40	Used_for Arg1:T59 Arg2:T20	
R41	Used_for Arg1:T59 Arg2:T21	
R43	Before Arg1:T61 Arg2:T60	
R44	Has_Frequency Arg1:T53 Arg2:T76	
R45	Experiences Arg1:T77 Arg2:T23	
R46	Experiences Arg1:T77 Arg2:T53	
R47	Used_for Arg1:T62 Arg2:T23	
R48	Has_Frequency Arg1:T62 Arg2:T78	
R49	Before Arg1:T23 Arg2:T53	
R50	Has_Frequency Arg1:T53 Arg2:T79	
R51	Experiences Arg1:T80 Arg2:T63	
R52	Has_Frequency Arg1:T63 Arg2:T81	
R53	Experiences Arg1:T80 Arg2:T53	
T98	PROC 1289 1296	estudio
#85	AnnotatorNotes T98	C0681814; research study; Research Activity
R54	Has_Duration_or_Interval Arg1:T98 Arg2:T83	
T99	Neg_cue 1358 1360	no
T100	CONC 1369 1383	modificaciones
A2	Assertion T100 Negated
R55	Negation Arg1:T99 Arg2:T100	
R57	Has_Route_or_Mode Arg1:T25 Arg2:T85	
R58	Has_Route_or_Mode Arg1:T25 Arg2:T86	
R59	Overlap Arg1:T54 Arg2:T69	
R60	Overlap Arg1:T54 Arg2:T24	
R61	Used_for Arg1:T28 Arg2:T65	
R62	Has_Route_or_Mode Arg1:T28 Arg2:T87	
R63	Has_Route_or_Mode Arg1:T28 Arg2:T88	
R64	Used_for Arg1:T29 Arg2:T36	
R65	Negation Arg1:T89 Arg2:T37	
R66	Used_for Arg1:T32 Arg2:T38	
R67	Used_for Arg1:T30 Arg2:T38	
R68	Before Arg1:T30 Arg2:T32	
R69	Causes Arg1:T16 Arg2:T40	
R70	Experiences Arg1:T91 Arg2:T16	
R71	Experiences Arg1:T91 Arg2:T55	
R72	Experiences Arg1:T91 Arg2:T38	
R74	Experiences Arg1:T91 Arg2:T40	
R76	Used_for Arg1:T33 Arg2:T41	
R77	Before Arg1:T33 Arg2:T32	
R78	Has_Frequency Arg1:T34 Arg2:T92	
R79	Has_Frequency Arg1:T34 Arg2:T93	
T102	Quantifier_or_Qualifier 2335 2342	basales
#86	AnnotatorNotes T102	C1442488; Baseline; Quantitative Concept
R80	Has_Quantifier_or_Qualifier Arg1:T35 Arg2:T102	
R81	Used_for Arg1:T34 Arg2:T68	
R82	Experiences Arg1:T94 Arg2:T39	
R83	Experiences Arg1:T94 Arg2:T27	
R84	Used_for Arg1:T32 Arg2:T56	
R85	Used_for Arg1:T34 Arg2:T27	
R86	Has_Route_or_Mode Arg1:T39 Arg2:T95	
R87	Experiences Arg1:T94 Arg2:T68	
R88	Experiences Arg1:T94 Arg2:T35	
R89	Before Arg1:T63 Arg2:T53	
R90	Before Arg1:T69 Arg2:T25	
T103	Observation 1919 1932	bien tolerado
R92	Before Arg1:T36 Arg2:T37	
R93	Experiences Arg1:T91 Arg2:T41	
R95	Before Arg1:T58 Arg2:T19	
T104	Observation 2131 2144	bien tolerada
R42	Has_Quantifier_or_Qualifier Arg1:T69 Arg2:T75	
R56	Before Arg1:T69 Arg2:T24	
R6	Overlap Arg1:T36 Arg2:T103	
#87	AnnotatorNotes T103	C5684674; patient tolerated procedure well; Finding
#88	AnnotatorNotes T104	C5684674; patient tolerated procedure well; Finding
R73	Overlap Arg1:T32 Arg2:T104	
T105	Quantifier_or_Qualifier 1384 1411	clínicamente significativas
A3	Assertion T105 Negated
R96	Has_Quantifier_or_Qualifier Arg1:T100 Arg2:T105	
R97	Negation Arg1:T99 Arg2:T105	
R4	Experiences Arg1:T66 Arg2:T46	
R15	Experiences Arg1:T66 Arg2:T51	
#89	AnnotatorNotes T96	C0205360; Stable status; Qualitative Concept
#90	AnnotatorNotes T100	C0443172; Changed status; Quantitative Concept
R16	Before Arg1:T25 Arg2:T100	
#91	AnnotatorNotes T105	C5209294; Clinical relevance; Intellectual Product
A4	Experiencer T66 Patient
A5	Experiencer T70 Patient
A6	Experiencer T72 Patient
A7	Experiencer T77 Patient
A8	Experiencer T80 Patient
A9	Experiencer T82 Patient
A10	Experiencer T91 Patient
A11	Experiencer T94 Patient
